The American Physiological Society Press Release

press release logo

APS Contact: APS Communications Office

Email: communications@the-aps.org

Phone: 301.634.7209

Twitter: @APSPhysiology


One Protein, Many Fascinating Roles

Savannah, Ga. (September 2, 2015)—Endothelin (ET) is a peptide produced by cells in the blood vessels and has powerful vessel-constricting effects. Although endothelin is mainly associated with its role in blood pressure control and cardiovascular diseases, it continues to appear in other physiological functions and diseases. During the 14th International Conference on Endothelin: Physiology, Pathophysiology and Therapeutics, “Novel Integration” will showcase the breadth of endothelin research. Presentations will discuss the role of endothelin in vessel dysfunction in the brain, cognitive decline, sickle cell disease and skin pigmentation. “It is fascinating that one peptide can exert so many biological actions,” says symposia chair Adviye Ergul, MD, PhD, one of the conference organizers.

The symposium’s keynote presentation is “ET-1 and Neurovascular Coupling.” Normally, brain blood flow responds immediately to changes in blood pressure and nutrients and oxygen demands. Presenter Constantino Iadecola, PhD, will discuss what happens when blood vessels and brain cells do not communicate effectively, called “neurovascular uncoupling.” The brain either receives too little blood, leading to temporary loss of oxygen and stroke, or too much blood flow, resulting in hemorrhage. Dr. Iadecola will address the role of ET-1 in neurovascular uncoupling observed in hypertension and sleep apnea and the potential of targeting its receptor, endothelin A, as a treatment.

The symposium will be held Saturday, September 5, from 10:30 AM to 12 PM EDT in Ballroom A of the Hyatt Regency Savannah.

Symposia X: Novel Integration
Chairs: David Webb, PhD, University of Edinburgh, UK
Adviye Ergul, MD, PhD, Georgia Regents University

“ET and Neurovascular Coupling”
Constantino Iadecola, Weill Cornell Medical College

“Relationship of Endothelin-1 and NLRP3 Activation in HT22 Hippocampal Cells: Relevance to Cognitive Decline in Diabetes”
Rebecca Ward, Georgia Regents University

“Endothelin 3 Regulates Pigment Production and Coat Color in Mice”
Javier Pino, Florida International University

“Endothelin Receptor Antagonism in Sickle Cell Nephropathy”
Olivia Lenoir, INSERM, Paris

“ETA Receptor Blockade Inhibits Leukocyte Activation and Adhesion in Sickle Cell Disease”
Diana Gutsaeva, Georgia Regents University

NOTE TO JOURNALISTS: To read the full abstract of a presentation, please contact the APS Communications Office or 301-634-7209. Find more research highlights in the APS Press Room.

Physiology is the study of how molecules, cells, tissues and organs function in health and disease. Established in 1887, the American Physiological Society (APS) was the first U.S. society in the biomedical sciences field. The Society represents more than 10,500 members and publishes 15 peer-reviewed journals with a worldwide readership.

 


RelatedItems

Vitamin C: The Exercise Replacement?

Released September 4, 2015 - Exercise improves health in overweight and obese adults but can be hard to incorporate into a daily routine. New findings show that taking vitamin C supplements daily instead can have similar cardiovascular benefits as regular exercise in these adults. This study will be presented at 14th International Conference on Endothelin: Physiology, Pathophysiology and Therapeutics in Savannah, Ga.

International Experts Talk Cancer, Sickle Cell, Diabetic Nephropathy Therapies at Endothelin Meeting in Savannah

Released September 2, 2015 - Endothelin (ET) plays a role in many functions throughout the body, including blood vessel constriction and blood pressure regulation and in a number of disease pathologies. Insights gained through the study of ET have great therapeutic potential for health and disease. As ET experts convene for the 14th International Conference on Endothelin: Physiology, Pathophysiology and Therapeutics, the translational aspect of ET research will take center stage during the “Endothelin Therapeutics—Where Are We?” symposium.

New Hope for Lou: Unexplored Therapeutic Targets for ALS

Released September 3, 2015 - No cures exist for amyotrophic lateral sclerosis (ALS), and the only approved therapy slows the progression by only a few months. A new study identifies a promising unexplored avenue of treatment for ALS, the endothelin system. This study will be presented at 14th International Conference on Endothelin: Physiology, Pathophysiology and Therapeutics in Savannah, Ga.

IV Administration of Endothelin B Receptor Drug Reduces Memory Loss, Oxidative Stress in Alzheimer’s Disease

Released September 4, 2015 - An estimated 5.3 million people in the U.S. suffer from Alzheimer’s disease (AD). The five current FDA-approved AD medications only help mask the disease symptoms instead of treating the underlying disease. In a new study presented at the 14th International Conference on Endothelin: Physiology, Pathophysiology and Therapeutics, researchers used IRL-1620, a chemical that binds to endothelin B receptors, to treat AD in rats.

From: 
Email:  
To: 
Email:  
Subject: 
Message:

~/Custom.Templates/PressRelease.aspx